Evidence map›Paper›PMID 33170359›Full record

ArticleMedical oncology (Northwood, London, England)2020

Association between the CEBPA and c-MYC genes expression levels and acute myeloid leukemia pathogenesis and development.

Adrian Krygier, Dagmara Szmajda-Krygier, Aleksandra Sałagacka-Kubiak, Krzysztof Jamroziak, Marta Żebrowska-Nawrocka, Ewa Balcerczak

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Shift of N-MYC Oncogene Expression in AML Patients Carrying the FLT3-ITD Mutation.Pathophysiology : the official journal of the International Society for Pathophysiology · 2023
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Adrian KrygierLaboratory of Molecular Diagnostics and Pharmacogenomics, Department of Pharmaceutical Biochemistry and Molecular Diagnostics, Medical University of Lodz, Muszynskiego 1 Street, 90-151, Lodz, Poland. adrian.krygier@umed.lodz.pl.ORCID https://orcid.org/0000-0003-1525-1577
Dagmara Szmajda-KrygierLaboratory of Molecular Diagnostics and Pharmacogenomics, Department of Pharmaceutical Biochemistry and Molecular Diagnostics, Medical University of Lodz, Muszynskiego 1 Street, 90-151, Lodz, Poland.ORCID https://orcid.org/0000-0002-9524-6032
Aleksandra Sałagacka-KubiakLaboratory of Molecular Diagnostics and Pharmacogenomics, Department of Pharmaceutical Biochemistry and Molecular Diagnostics, Medical University of Lodz, Muszynskiego 1 Street, 90-151, Lodz, Poland.ORCID https://orcid.org/0000-0002-6360-1538
Krzysztof JamroziakDepartment of Hematology, Institute of Hematology and Transfusion Medicine, Chocimska 5 Street, 00-791, Warsaw, Poland.ORCID https://orcid.org/0000-0001-7207-8534
Marta Żebrowska-NawrockaLaboratory of Molecular Diagnostics and Pharmacogenomics, Department of Pharmaceutical Biochemistry and Molecular Diagnostics, Medical University of Lodz, Muszynskiego 1 Street, 90-151, Lodz, Poland.ORCID https://orcid.org/0000-0001-7478-7860
Ewa BalcerczakLaboratory of Molecular Diagnostics and Pharmacogenomics, Department of Pharmaceutical Biochemistry and Molecular Diagnostics, Medical University of Lodz, Muszynskiego 1 Street, 90-151, Lodz, Poland.ORCID https://orcid.org/0000-0001-5257-2914
Medical University of Lodz · PLInstytut Hematologii i Transfuzjologi · PL

Funding

funds of the Faculty of Pharmacy, Medical University of Lodz 502-03/3-015-02/502-34-088funds of the Faculty of Pharmacy, Medical University of Lodz grant nos. 502-03/3-015-02/502-34-089Statutory funds of the Department of Pharmaceutical Biochemistry and Molecular Diagnostics, Medical University of Lodz 503/3-015-02/503-31-001)
6 · The paper itself

Abstract

CEBPA and c-MYC genes belong to TF and play an essential role in hematologic malignancies development. Furthermore, these genes also co-regulate with RUNX1 and lead to bone marrow differentiation and may contribute to the leukemic transformation. Understanding the function and full characteristics of selected genes in the group of patients with AML can be helpful in assessing prognosis, and their usefulness as prognostic factors can be revealed. The aim of the study was to evaluate CEBPA and c-MYC mRNA expression level and to seek their association with demographical and clinical features of AML patients such as: age, gender, FAB classification, mortality or leukemia cell karyotype. Obtained results were also correlated with the expression level of the RUNX gene family. To assess of relative gene expression level the qPCR method was used. The expression levels of CEBPA and c-MYC gene varied among patients. Neither CEBPA nor c-MYC expression levels differed significantly between women and men (p=0.8325 and p=0.1698, respectively). No statistically significant correlation between age at the time of diagnosis and expression of CEBPA (p=0.4314) or c-MYC (p=0.9524) was stated. There were no significant associations between relative CEBPA (p=0.4247) or c-MYC (p=0.4655) expression level and FAB subtype and mortality among the enrolled patients (p=0.5858 and p=0.8437, respectively). However, it was observed that c-MYC and RUNX1 expression levels were significantly positively correlated (rS=0.328, p=0.0411). Overall, AML pathogenesis involves a complex interaction among CEBPA, c-MYC and RUNX family genes.

Indexed as

AdolescentAdultAgedAged, 80 and overCCAAT-Enhancer-Binding ProteinsCore Binding Factor Alpha 2 SubunitFemaleHumansLeukemia, Myeloid, AcuteMaleMiddle AgedProto-Oncogene Proteins c-mycRNA, MessengerYoung AdultCCAAT-Enhancer-Binding ProteinsCEBPA protein, humanCore Binding Factor Alpha 2 SubunitMYC protein, humanProto-Oncogene Proteins c-mycRNA, MessengerRUNX1 protein, humanAdult leukemiaAMLCEBPA genec-MYC geneGene expression levelqPCRTranscription factors

Identifiers

PMID33170359
PMCPMC7655568
OpenAlexW3105294196

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.